6269-91-6

Basic information

• Product Name: 2-Methyl-5-nitrobenzenesulfonamide
• Synonyms: IFLAB-BB F1084-0158;BUTTPARK 52\04-61;2-METHYL-5-NITROBENZENESULPHONAMIDE;2-METHYL-5-NITROBENZENESULFONAMIDE;4-Nitro-2-toluenesulfonamide;BENZENESULFONAMIDE,2-METHYL-5-NITRO-;2-methyl-5-nitrobenzene-1-sulfonamide;2-Methyl-5-nitro-1-benzenesulfonamide
• CAS NO: 6269-91-6
• Molecular Formula: C₇H₈N₂O₄S
• Molecular Weight: 216.21
• EINECS: 220-358-3
• Product Categories: Benzene derivates
• Mol File: 6269-91-6.mol
• Article Data: 17

Chemical Properties

• Melting Point: 197-199
• Boiling Point: 431.4 °C at 760 mmHg
• Flash Point: 214.7 °C
• Appearance: /
• Density: 1.475 g/cm³
• Vapor Pressure: 1.2E-07mmHg at 25°C
• Refractive Index: 1.596
• Storage Temp.: 2-8°C
• Solubility: Chloroform (Sparingly), Methanol (Slightly)
• PKA: 9.56±0.60(Predicted)
• CAS DataBase Reference: 2-Methyl-5-nitrobenzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Methyl-5-nitrobenzenesulfonamide(6269-91-6)
• EPA Substance Registry System: 2-Methyl-5-nitrobenzenesulfonamide(6269-91-6)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 6269-91-6(Hazardous Substances Data)

Usage

Uses

2-Methyl-5-nitrobenzenesulfonamide is a chemical reagent in the synthesis of good inhibitors of cancer-related carbonic anhydrase. Also used in the synthesis of novel deacetylase inhibitors used in anti-tumor therapy.

InChI:InChI=1/C7H8N2O4S/c1-5-2-3-6(9(10)11)4-7(5)14(8,12)13/h2-4H,1H3,(H2,8,12,13)

Upstream product

• 121-02-8 2-methyl-5-nitrobenzene-1-sulfonyl chloride 
• 99-99-0 1-methyl-4-nitrobenzene 
• 99-55-8 2-methyl-5-nitroaniline 

Downstream Products

• 22952-24-5 6-nitrosaccharin 
• 299183-41-8 5-nitro-2-[(E)-2-(4-nitro-2-(aminosulfonyl)phenyl)ethenyl]benzene sulfonamide 
• 299183-42-9 5-amino-2-[(E)-2-(4-amino-2-(aminosulfonyl)phenyl)ethenyl]benzene sulfonamide 
• 22094-62-8 6-amino-1,2-benzisothiazole-3(2H)-one 1,1-dioxide 
• 84591-91-3 6-<4-(2-bromoethyl)benzenesulfonamido>saccharin 
• 6973-09-7 5-amino-2-methylbenzenesulfonamide 
• 1374832-49-1 6-(N₃-phenylureido)saccharin 
• 1374832-51-5 6-(N₃-(3-methoxyphenyl)ureido)saccharin 
• 1374832-53-7 6-(N₃-(4-methoxyphenyl)ureido)saccharin 
• 1374832-55-9 6-(N₃-(4-methylphenyl)ureido)saccharin 
• 1374832-57-1 6-(N₃-(3-chlorophenyl)ureido)saccharin 
• 1374832-59-3 6-(N₃-(4-chlorophenyl)ureido)saccharin 
• 1374832-61-7 6-(N₃-(3,4-dichlorophenyl)ureido)saccharin 
• 1374832-69-5 6-(N₃-(3-fluorophenyl)ureido)saccharin 

Relevant articles and documents

COMPOUNDS AND METHOD FOR TREATING CYTOKINE RELEASE SYNDROME

Disclosed herein are embodiments of a method for treating or preventing cytokine release syndrome (CRS). In certain embodiments, the method comprises administering a compound, or a salt, solvate, prodrug or pharmaceutical composition thereof, to a subject experiencing, or at risk of developing, CRS. The compound may be a kinase inhibitor, such as a JAK inhibitor and/or an IRAK inhibitor, and/or the compound may have a structure according to Formulas I, III, IV or VII. And the method may comprise administering the compound to a subject who is has received, is currently receiving, and/or will be receiving a cell therapy.

A convenient synthesis of 2-methoxycarbonyl-5-iodobenzene sulfonamide

A convenient and concise synthesis of 2-methyl-5-nitrobenzene sulfonamide can be achieved by sulfochlorination and ammoniation with p-nitrotoluene as raw materials for an 81.2 % yield. 6-Aminosaccharin can be produced via oxidation and reduction in a 64.3

In vitro inhibition effect and structure-activity relationships of some saccharin derivatives on erythrocyte carbonic anhydrase i and II

In this study, in vitro inhibitory effects of some saccharin derivatives on purified carbonic anhydrase I and II were investigated using CO2 as a substrate. The results showed that all compounds inhibited the hCA I and hCA II enzyme activities. Among the compounds, 6-(p-tolylthiourenyl) saccharin (6m) was found to be the most active one for hCA I activity (IC50 = 13.67 μM) and 6-(m-methoxyphenylurenyl) saccharin (6b) was found to be the most active one for hCA II activity (IC50 = 6.54 μM). Structure-activity relationships (SARs) study showed that, generally, thiourea derivatives (6l - v) inhibited more hCA I and hCA II than urea derivatives (6a-k). All compounds (excluding 6c and 6r) have higher inhibitory activity on hCA II than on hCA I.